Scientists test drug duo to reboot immune system against tough cancers
NCT ID NCT07219576
Summary
This early-stage trial is testing whether adding a pill called ruxolitinib to an immunotherapy drug (retifanlimab) is safe and can help control advanced lung or kidney cancer that has started growing again after prior immunotherapy. The study will enroll about 40 participants to find the best dose of ruxolitinib to use with the fixed immunotherapy dose. Participants will take the pill at home and visit the clinic every 4 weeks for infusions and checkups.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Diego Moores Cancer Center
RECRUITINGLa Jolla, California, 92093, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.